Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David O Azorsa

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Optimization of Transfection Conditions for siRNA ScreeningJustin J Montoya, David O Azorsa
Methods in Molecular Biology (Clifton, N.J.)|February 26, 2013
High-throughput RNAi screening for the identification of novel targetsMeredith C Henderson, David O Azorsa
Frontiers in Oncology|June 1, 2012
The genomic and proteomic content of cancer cell-derived exosomesMeredith C Henderson, David O Azorsa
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Data Analysis for High-Throughput RNAi ScreeningDavid O Azorsa, Megan A Turnidge, Shilpi Arora
Drug Discovery Today. Technologies|July 2, 2014
Genome scale cytometry: High content analysis for high throughput RNAi phenotype profilingDavid M Evans, David O Azorsa, Spyro Mousses
BMC Cancer|September 11, 2003
Phenotypic alterations in breast cancer cells overexpressing the nuclear receptor co-activator AIB1Sarah L Anzick, David O Azorsa, S Stoney Simons, et al.
Assay and Drug Development Technologies|May 18, 2010
A high-content RNAi-screening assay to identify modulators of cholesterol accumulation in Niemann-Pick type C cellsShilpi Arora, Christian Beaudry, Kristen M Bisanz, et al.
Pediatric Blood & Cancer|September 11, 2012
BIRC5 expression is a poor prognostic marker in Ewing sarcomaPooja Hingorani, Paul Dickman, Pamela Garcia-Filion, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 2, 2017
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cellsRanjan Bista, David W Lee, Oliver B Pepper, et al.
Cancer Research|March 3, 2007
Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplificationRiina Kuuselo, Kimmo Savinainen, David O Azorsa, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Optimization of Transfection Conditions for siRNA ScreeningJustin J Montoya, David O Azorsa
Methods in Molecular Biology (Clifton, N.J.)|February 26, 2013
High-throughput RNAi screening for the identification of novel targetsMeredith C Henderson, David O Azorsa
Frontiers in Oncology|June 1, 2012
The genomic and proteomic content of cancer cell-derived exosomesMeredith C Henderson, David O Azorsa
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Data Analysis for High-Throughput RNAi ScreeningDavid O Azorsa, Megan A Turnidge, Shilpi Arora
Drug Discovery Today. Technologies|July 2, 2014
Genome scale cytometry: High content analysis for high throughput RNAi phenotype profilingDavid M Evans, David O Azorsa, Spyro Mousses
BMC Cancer|September 11, 2003
Phenotypic alterations in breast cancer cells overexpressing the nuclear receptor co-activator AIB1Sarah L Anzick, David O Azorsa, S Stoney Simons, et al.
Assay and Drug Development Technologies|May 18, 2010
A high-content RNAi-screening assay to identify modulators of cholesterol accumulation in Niemann-Pick type C cellsShilpi Arora, Christian Beaudry, Kristen M Bisanz, et al.
Pediatric Blood & Cancer|September 11, 2012
BIRC5 expression is a poor prognostic marker in Ewing sarcomaPooja Hingorani, Paul Dickman, Pamela Garcia-Filion, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 2, 2017
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cellsRanjan Bista, David W Lee, Oliver B Pepper, et al.
Cancer Research|March 3, 2007
Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplificationRiina Kuuselo, Kimmo Savinainen, David O Azorsa, et al.
Pageof 3